Canaccord analyst Kyle Mikson initiated coverage of Olink with a Buy rating and $28 price target. The company provides a platform for protein measurement based on the Proximity Extension Assay, or PEA, technology, which has demonstrated "market-leading specificity, as well as high dynamic range and sensitivity," Mikson tells investors. The analyst, who believes Olink is poised for deeper penetration of its roughly $35B total addressable market, argues that the current share price does not reflect the company’s long-term growth potential.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on OLK:
- Maria Martin-Grau, at the University of Valencia, Spain is selected for the 2022 Novelties in Biomarkers award
- Olink to hold an investor day
- Announcing Olink® Flex, a new, unique and fully flexible low-plex proteomics solution using absolute quantification
- Olink reports third quarter 2022 financial results
- Olink announces milestone achievement of 1,000 peer-reviewed articles citing use of PEA technology
